New indications for superficial basal cell carcinoma and adolescent alopecia areata expanded treatment options, while psoriasis and rare disease candidates advanced through FDA review.
News|Articles|April 3, 2025
Daily Derm Times: April 3, 2025
Author(s)Emma Andrus, Editor
Listen
0:00 / 0:00
Key Takeaways
- The prevalence of atopic dermatitis is stable, but the disease burden is rising, highlighting the need for personalized treatment strategies.
- Early recognition and aggressive treatment of childhood-onset mucous membrane pemphigoid are essential to prevent permanent scarring.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
Advertisement
To stay up-to-date with the latest dermatology news, sign up to receive our
Atopic Dermatitis Insights on Global Prevalence, Health Care Implications, and the Impact of COVID-19
Researcher Jiyeon Oh shares results of a recent study that confirm the prevalence of AD is stable, but disease burden is rising.
Multicenter Study Sheds Light on Pediatric MMP
The study stated early recognition and aggressive treatment of childhood-onset MMP are essential to prevent permanent scarring.
Researchers Report Rare Case of Squamous Cell Carcinoma in Sun-Shielded Area in Epidermodysplasia Verruciformis
Researchers reported the case of a 28-year-old woman with epidermodysplasia verruciformis who developed SCC on a sun-protected scalp.
Why Atopic Dermatitis Treatment is Not “One Size Fits All,” According to Jiyeon Oh
Jiyeon Oh’s research confirms that a personalized approach is needed to treat all complexities associated with AD.
Reduced Cardiovascular Risk with Biologics in Psoriasis and PsA
Unlike biologics, nonbiologic systemic therapies showed a neutral or slightly increased cardiovascular risk, raising concerns about their long-term safety.
Advertisement
Related to this article
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
At week 112, at least 72% of patients on icotrokinra held PASI 90 and at least 44% held PASI 100, with no new safety signals reported.
Advertisement
Advertisement
Trending on Dermatology Times
1
JAK Inhibitor Safety in Atopic Dermatitis: Long-Term Epidemiology Data
2
Roflumilast Eases Sexual Difficulties in Psoriasis With Genital Involvement
3
No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis
4
Managing Treatment Expectations in Hidradenitis Suppurativa: What to Tell Patients Before Starting Therapy
5